The 2 analysts offering 12-month price forecasts for Can Fite Biopharma Ltd have a median target of 7.00, with a high estimate of 9.00 and a low estimate of 5.00. The median estimate represents a +354.55% increase from the last price of 1.54.
The current consensus among 2 polled investment analysts is to Buy stock in Can Fite Biopharma Ltd. This rating has held steady since October, when it was unchanged from a Buy rating.Move your mouse over past months for detail
Earnings and Sales Forecasts
Earnings per Share -$0.07
Reporting Date Dec 01
Earnings per Share
Move your mouse over a quarter or year to see how estimates have changed over time.